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ABSTRACT: Little attention has been paid to quality of life (QOL) in idiopathic
pulmonary fibrosis (IPF). Therefore, the aim of this study was to address this issue and
study the relationship between QOL, depressive symptoms, and breathlessness in these
patients.
Forty-one IPF patients and 41 healthy persons matched for age and sex completed
the World Health Organization Quality of Life assessment instrument-100. The IPF
patients also completed the Beck Depression Inventory, the Bath Breathlessness Scale,
a social support questionnaire and a question concerning perceived seriousness of illness.
Compared to the control group, QOL in IPF patients was mainly impaired in the
domains "physical health" and "level of independence". A number of relationships were
found between pulmonary function tests and QOL. The QOL facet "negative feelings"
was highly associated with scores on depression. Subjective breathlessness was related
to depressive symptoms and QOL. Moreover, sex and effective/emotional breath-
lessness predicted overall QOL.
In conclusion, the impairment of the quality of life areas "physical health" and "level
of independence" are important issues in idiopathic pulmonary fibrosis. Subjective
breathlessness, especially the effective/emotional scale, seems related to quality of life
and depressive symptoms. Rehabilitation programmes are needed that are aimed at
physiological aspects and psychosocial aspects of idiopathic pulmonary fibrosis in order
to enhance the quality of life of these patients.
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Idiopathic pulmonary fibrosis (IPF) or cryptogenic
fibrosing alveolitis is a common interstitial lung disease
of unknown aetiology. However, the clinical entity is
well-defined. IPF is defined as "a specific form of
chronic fibrosing interstitial pneumonia limited to the
lung and associated with the histologic appearance of
usual interstitial pneumonia (UIP) on surgical obtained
lung biopsy" [1]. Most importantly, the diagnosis of
IPF is made by exclusion of all known causes of
fibrosing alveolitis [1, 2].
The patient demonstrates breathlessness, non-
productive cough and bibasilar and inspiratory dry
rates, and there are findings of finger clubbing. Con-
stitutional symptoms such as weight loss, malaise, and
fatigue may be present. Shortness of breath is usually
the most salient and disabling symptom and is usually
present at least 6 months before presentation [1].
The age at onset varies from 40 – 70 yrs. The clinical
course is highly variable. However, in general, the
prognosis is poor [1, 3 – 5]. The median survival after
diagnosis is v5 yrs [1, 2, 5]. IPF is a potentially fatal
disorder without spontaneous remission. Therefore, the
majority of the patients require therapy. Subjective
improvement occurs frequently. However, objective
improvement in the decrease of symptoms, radio-
graphic clearing, or physiological improvement,
assessed by lung functions tests, occurs in v25% of
treated patients [1, 2, 5, 6].
IPF patients have a limited life expectancy. In cancer
patients, much is known about the impact of a short
life expectancy. In a previous study [7], some IPF
patients were shocked by the condition of other more
severe IPF patients. This seems to indicate that patients
are not fully aware that they have a fair chance of dying
within a few years.
Regarding the quality of life (QOL) of IPF patients,
little is known [1, 7]. Recently, a study among IPF
patients with the aim of identifying the aspects of QOL
that are relevant to this population was conducted.
Results indicated that hobbies/leisure activities, mobi-
lity, transport, social relationships, working capacity,
energy, and doing things slower were aspects relevant
to IPF patients9 QOL [7].
The severity of IPF, the poor prognosis and, in
general, disappointing response to therapy resulting in
a reduced life expectancy, emphasize the importance of
this issue. Therefore, the aims of this study were to
assess the QOL and depressive symptoms in IPF
patients, the relationship between the QOL factors
"fatigue" and "negative feelings". The study also aims
to identify factors that are related to QOL (perceived
illness severity, illness duration), and to identify
impaired aspects of QOL to guide future rehabilitation
programmes. Based on a previous study [7], QOL
measurement was expanded with additional social
support questions. Shortness of breath is a prominent
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feature of IPF and it can have a major impact on
patients9 QOL [8]. Therefore, breathlessness was also
measured with the aim of examining the relationship
between QOL and objective (clinical data) as well as
subjective breathlessness, and establishing the influence




Patients suffering from IPF from nine participating
Dutch hospitals (Hospital Gelderse Vallei, Bennekom;
Ignatius Hospital, Breda; Medical Centre Den Bosch,
Den Bosch; St. Anna Hospital, Geldrop; Twee Steden
Hospital, Tilburg; St. Radboud Hospital and Rehabi-
litation Centre Dekkerswald, Nijmegen; District Hos-
pital Middle Twente, Hengelo; Maasland Hospital,
Sittard; and University Hospital, Maastricht) were
selected. The diagnosis of IPF was based on consistent
clinical features, together with radiographical findings,
bronchoalveolar lavage fluid analysis results and
finally, biopsy proven with histological characteristics
of UIP consistent with IPF [1, 3].
In the context of two other studies [9], 555 persons
had indicated their willingness to participate in a study
on QOL. From the group of participants who returned
a completed test-booklet (n~356; 64.1%), matched
healthy control subjects (n~41) were selected on the
basis of sex and age (table 1). These control subjects
were used in order to compare their World Health
Organization Quality of Life assessment instrument-
100 (WHOQOL-100) scores with those of the IPF
subjects.
Measures
All subjects completed the WHOQOL-100 (Dutch
version [10]), a cross-culturally developed, generic,
multidimensional QOL measure [11, 12]. It consists of
100 items assessing 24 facets of QOL within six
domains (physical health, psychological health, level
of independence, social relationships, environment, and
spirituality/religion/personal beliefs) and a general
evaluative facet (overall QOL and general health) [1].
Each facet is represented by four items. The response
scale is a 5-point Likert scale. Scores on each facet and
domain can range from 4 – 20. With the exception of
the facets "pain and discomfort", "negative feelings",
and "dependence on medication or treatments", where
low scores indicate higher QOL, higher scores indicate
a better QOL. The reliability and validity of the
instrument, which has also been tested in sarcoidosis,
are good [13 – 15]. The test-retest reliability is satisfac-
tory [9].
Patients also completed the Beck Depression Inven-
tory (BDI) [16], a well-validated index of depression
which correlates well with diagnostic criteria. This
instrument consists of statements which are arranged in
21 groups of four possible responses. Patients were
asked to select one statement from each group that best
described the way they felt the previous week. Each
answer is scored on a four-point Likert-type scale from
0 – 3. A summation of the ratings in the 21 groups
indicates the severity of depression (possible range
0 – 63). A patient with a total score of 15 or above was
considered to have significant depressive symptoms. In
order to control the physical effects of the illness on
mood, items referring to physical symptoms were
excluded. The scale based on the remaining 15 items
was entitled the Cognitive Depression Inventory (CDI).
This appears to be a valid way to prevent confounding
relationships [17].
Patients also completed the Bath Breathlessness
Scale (BBS) [18]. This is a 35-item adjective subjective
breathlessness scale measuring four aspects of breath-
lessness: physical sensations, effective/evaluative
descriptions, low energy items, and hyperventilation/
speechless items. In addition, patients were asked to
indicate on an 8-point response scale how breathless
they had been during the last 2 weeks and were asked
whether their breathlessness is brief, periodic or
continuous. Apart from the four separate scale scores
and the severity score, a total BBS score can be
calculated. Patients with a respiratory, oncology or
cardiac diagnosis had provided, in interviews, 63
descriptions of breathlessness. Subsequently, expert
health professionals sorted these descriptions according
to similarity and judged them on frequency and
Table 1. – Characteristics of the idiopathic pulmonary
fibrosis (IPF) patient population and the control group
IPF group Control group
Demographic characteristics
Number of cases n 41 41
Sex male/female 15/26 15/26
Age yrs 63.5 (38 – 80) 64.0 (45 – 83)
Smoking yes/no/missing 4/35/6
Medical characteristics
Oxygen use yes/no 14/27
If yes now often? 24 h a
day/sometimes
6/8
Steroid use at time of study
yes/no
28/13
Time since diagnosis yrs 5.8¡5.4
FEV1 % pred 70.1¡21.5
TL,CO % pred 45.3¡14.9
PO2 at rest kPa 9.1¡1.7
PO2 during exercise kPa 7.0¡1.2












Data are expressed in means, (range) or as mean¡sd.
FEV1: forced expiration volume in one second; TL,CO:
transfer factor of the lung for carbon monoxide; PO2: arterial
oxygen tension; BDI: Beck Depression Inventory; CDI:
Cognitive Depression Index.
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severity. The final structure was established using
multivariate analyses [18].
Patients completed 14 questions which were specific-
ally developed for chronically ill persons [19]. These
questions refer to three different kinds of social
support: practical support ("Do you get practical
support from your children?"), emotional support
("Do you get emotional support from your partner?"),
and understanding ("Do you get understanding from
your children?"). Each type of social support question
was asked in relation to a set of possible support
providers such as the patient9s partner, children and
neighbours. A total social support score is calculated
by summing-up the general questions of the three types
of support. In addition, on a 4-point rating scale (not at
all serious, not serious, serious, very serious) patients
were asked how serious they thought their IPF was.
Finally, patients9 physicians provided information
concerning illness duration and patients provided
information concerning symptoms.
Assessment procedures
Lung function measures included forced expiratory
volume in one second (FEV1) and inspiratory vital
capacity measured with a pneumotachograph. Mea-
sures were selected from the three best efforts. The
transfer factor of the lung for carbon monoxide
(TL,CO) was measured by the single breath method
(Masterlab; Jaeger, Würzburg, Germany). Values were
expressed as a percentage of those predicted [20].
Exercise capacity
Patients performed a symptom limited incremental
exercise test on an electronically braked cycle ergo
meter (Cornival 400, Lode, Groningen, the Nether-
lands). After a period of rest and 2 min of unloaded
pedalling, a progressively increasing work rate test was
started in order to determine peak work rate and
oxygen uptake of the subject. The work rate increase
was set at 10 W?min-1 for each patient and
15 – 30 W?min-1 for the healthy volunteers, depending
upon their training status. Pedalling frequency was
selected by the subjects (between 60 – 70 rpm) and held
constant throughout the test. Breath-by-breath gas
exchange was measured throughout the test by a
ventilated hood system (Oxyconbeta, Jaeger, Bunnik,
the Netherlands). An infrared electrode was placed on
a finger to measure oxygen saturation (Fasttrac, Sensor
Medics Co., Anaheim, CA, USA). Heart rate was
measured throughout the test using a Sport tester
(PE3000, Polar Electro cy, Kempele, Finland). At rest
and during maximum exercise, arterial blood samples
were taken and arterial blood gas analyses were
performed.
Statistical procedure
Data are expressed as mean¡sd unless otherwise
stated. Within the IPF group, t-tests were used for the
following comparisons: oxygen use versus no oxygen
use for QOL; steroid use versus no steroid use for QOL
and dyspnoea. Furthermore, t-tests were used to test
for differences between the IPF and healthy groups. A
p-value of v0.005 was considered to be statistically
significant. In the IPF group Pearson, or where
appropriate, Spearman correlations were used to
study: 1) the association between FEV1, TL,CO, arterial
oxygen tension (Pa,O2) at rest, Pa,O2 after exertion,
Pa,O2 difference and illness duration versus the QOL
(including the additional social support questions) and
seriousness of the illness; 2) the association between
subjective breathlessness versus QOL; 3) the relation-
ship between seriousness of IPF versus QOL and the
BDI/CDI; and 4) the association between the
WHOQOL-100 facets "negative feelings" and "energy
and fatigue" versus the BDI/CDI. Stepwise multiple
regression was performed to establish the influence of
(objective and subjective) breathlessness on overall
QOL. A p-valuev0.05 was considered statistically
significant. All analyses were performed using the
Statistical Package for Social Sciences (SPSS) for
Windows (SPSS, Chicago, IL, USA).
Results
The demographic (also healthy group), medical and
psychological characteristics, as well as complaints of
the IPF group are summarized in table 1. The
comparison of QOL scores between the IPF group
and the control group are shown in table 2. It appeared
that the QOL of the IPF group was impaired with
regard to their general QOL and the domains "physical
health" and "level of independence". At facet level, IPF
patients had problems with "pain and discomfort",
"energy and fatigue", "sleep and rest", "activities of
daily living", "dependence on medication or treat-
ments", "working capacity", "ability to acquire new
information and skills", and "participating in, and
possibilities for recreation/leisure". The QOL of IPF
patients using oxygen did not differ from IPF patients
who did not use oxygen. Steroid use was unrelated to
dyspnoea and QOL.
Patients9 FEV1 appeared to be related to the
domains "psychological health", "social relationships",
and "environment". Furthermore, FEV1 was signific-
antly correlated with "overall QOL", "pain and
discomfort", "positive feelings", "self-esteem", "negative
feelings", and "participating in, and possibilities for
recreation/leisure" (table 3). Arterial oxygen saturation
(Sa,O2) decrease on exertion was related to the QOL
domain "level of independence" and the facet "trans-
port and Pa,O2 at rest" was positively correlated with
patients9 "overall QOL". The TL,CO was not associated
with any QOL aspect (table 3). No relationship was
found between subjective breathlessness and the ques-
tion on perceived seriousness of illness, on the one
hand, and lung function parameters or illness duration,
on the other hand. With regard to the social support
questionnaire, emotional support was negatively
related to FEV1, whereas "understanding" and the
total social support score were negatively related to
Sa,O2 decrease on exertion. Illness duration was
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associated with "ability to acquire new information and
skills" (table 3).
Perceived seriousness of illness was related to the
QOL domains "physical health" (r~-0.47; pv0.05)
and "level of independence" (r~-0.44; pv0.05) and the
QOL facets "pain and discomfort" (r~0.49; pv0.05),
"energy and fatigue" (r~-0.64; pv0.005), "dependence
on medication or treatments" (r~-0.50; pv0.05),
"working capacity" (r~-0.57; pv0.01), and "sexual
activity" (r~0.66; pv0.005). Seriousness of illness
appeared to be unrelated to depressive mood (BDI/
CDI).
The number of patients with a BDI score of ¢15
was eight (23.5%; n~34), whereas nine patients (26.5%;
n~34) had a CDI score of ¢9. Both BDI and CDI
scores correlated highly with the WHOQOL-100 facet
score "negative feelings" (r~0.73 and r~0.75;
pv0.001, respectively). The correlations between the
BDI and CDI scores, and the WHOQOL-100 "energy
and fatigue" facet scores were not significant. The BDI
was related to the breathlessness scale "affective/
emotional" (r~0.55; pv0.01) whereas the CDI was
correlated with the breathlessness scales "affective/
emotional" (r~0.53; pv0.01) and "low energy"
(r~0.44; pv0.05).
The correlations between subjective breathlessness
Table 2. – Quality of life (QOL) scores measured with the World Health Organization Quality of Life assessment
instrument-100 (WHOQOL-100) of the idiopathic pulmonary fibrosis (IPF) patient population compared to the matched
control group
IPF group Control group T-value
Overall QOL and general health 13.1¡3.0 16.5¡2.1 5.98**
Physical health 12.7¡2.3 15.9¡2.2 6.03**
Pain and discomfort 11.4¡2.9 8.5¡3.1 -3.81**
Energy and fatigue 10.6¡2.9 15.1¡2.9 6.61**
Sleep and rest 14.5¡3.5 16.9¡3.4 3.09ƒ
Psychological health 13.8¡2.4 15.1¡2.0 ns
Self-esteem 13.0¡2.6 15.1¡3.1 3.15ƒ
Level of independence 12.0¡2.9 17.2¡2.0 8.78**
Mobility 12.1¡3.3 16.8¡2.8 6.80**
Activities of daily living 12.5¡3.6 17.1¡2.0 6.66**
Dependence on medication or treatments 12.0¡4.0 6.0¡2.2 -7.60**
Working capacity 10.6¡3.9 16.7¡2.9 7.56**
Environment 15.1¡1.8 16.0¡1.9 ns
Ability to acquire new information and skills 14.2¡2.2 16.1¡2.6 3.34ƒ
Participating in and possibilities for recreaction/leisure 13.6¡3.3 16.1¡2.9 3.53ƒ
Data are expressed as mean¡sd. Domains are in bold type and facets belonging to these domains are listed underneath.
Nonsignificant facets have not been included in the above table. Higher scores on QOL facets and domains indicate better
QOL. Exceptions are the facets ’pain and discomfort’, ’negative feelings’, and ’dependence on medication or treatments’.
ƒ: pv0.005; **: pv0.001; ns: nonsignificant.
Table 3. – Significant correlations between World Health Organization Quality of Life assessment instrument-100
(WHOQOL-100) of the idiopathic pulmonary fibrosis (IPF) patient population and forced expiration volume in one second






Overall QOL and general health 0.36 0.41
Physical health





Level of independence 0.55
Social relationships 0.38
Environment 0.33
Ability to acquire new information and skills 0.40




Total social support -0.60
All correlations are significant at pv0.05 level. Higher scores on quality of life (QOL) facets and domains indicate better
QOL. Exceptions are the facets ’pain and discomfort’ and ’negative feelings’. PO2: arterial oxygen tension.
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and QOL are presented in table 4. As can be seen,
shortness of breath is related to most domains and
facets of patients9 QOL. Exceptions are the QOL facets
"sleep and rest", "mobility", "dependence on medica-
tion", "health and social care", "ability to acquire new
information and skills", and "transport" as well as the
domain "spirituality/religion/personal beliefs" which
showed no significant correlation with any of the
BBS scales or the total BBS score.
Subsequently, a stepwise multiple regression analysis
was performed to examine the relationship between
breathlessness and QOL further. A conservative
strategy was adopted in which the demographic
variables age and sex were entered as a block in the
first step of the regression analysis and the pulmonary
function parameters (FEV1, TL,CO, and Pa,O2 differ-
ence score) as a block in the second step of the analysis
to statistically adjust for their influence, despite
negligible associations with overall QOL and breath-
lessness. In the final model with overall QOL as
dependent variable (R2~0.98; F(6,2)~20.8, pv0.05),
sex (b~-0.74; t~-5.3, pv0.05) and effective/emotional
descriptions of breathlessness (b~-1.16; t~-7.3;
pv0.05) were the only factors that significantly
contributed to the prediction of overall QOL.
Age and sex were not associated with depression
(BDI and CDI), negative feelings, duration of illness,
FEV1, TL,CO, and Sa,O2 decrease on exertion. Age was
related to both perceived seriousness of illness
(r~-0.44; pv0.05; n~21) and the BBS scale "physical
sensations" (r~-0.38; pv0.05), whereas sex was not.
Discussion
The QOL of the IPF patients was mainly impaired in
the domains "physical health" and "level of independ-
ence" compared with a matched healthy control group.
In general, these results are similar to those found in
another common interstitial lung disease, i.e. sarcoi-
dosis [13].
In contrast to previous findings in sarcoidosis [13],
the FEV1 appeared to be related to QOL. Especially,
"psychological health" (domain level), "social relation-
ships" (domain level), "environment" (domain level),
"overall QOL", "pain", "positive feelings", "negative
feelings", "self-esteem", and "recreation/leisure"
appeared to be related to the FEV1. When comparing
the aspects of QOL associated with FEV1, with the
facets in which the QOL of IPF patients is impaired, it
appears that the results are only congruent for "overall
QOL", "pain", "self-esteem", and "recreation/leisure". It
is striking that the QOL domains impaired in IPF
patients are not associated with FEV1. Moreover, the
other lung function parameters were hardly related to
patients9 QOL. An exception was Sa,O2 decrease during
exertion, which was related to the QOL domain "level
of independence" and the facet "transport". Although
caution in the interpretation is warranted, as the
sample size of the studied patient population was
rather small, it is reasonable to assume that although
FEV1 was related to QOL, lung function parameters,
except Sa,O2 decrease during exertion, are not reliable
indicators of QOL impairment in IPF patients.
Table 4. – Significant correlations between World Health Organization Quality of Life assessment instrument-100
(WHOQOL) scores of the idiopathic pulmonary fibrosis (IPF) patient and population subjective dyspnoea (Bath
Breathlessness Scale (BBS)) scores
Severity# I II III IV Total
Overall QOL and general health -0.55ƒ -0.56§
Physical health -0.38§ -0.59ƒ -0.48§
Pain and discomfort 0.52**
Energy and fatigue -0.57 -0.46§ -0.54ƒ -0.74ƒ -0.69ƒ
Psychological health -0.45§ -0.66ƒ -0.63ƒ
Positive feelings -0.44§ -0.52ƒ -0.55§
Cognitive functions} -0.53ƒ -0.46§ -0.52§
Self-esteem -0.49ƒ
Bodily image and appearance -0.43§ -0.44§
Negative feelings 0.56ƒ 0.68** 0.68ƒ
Level of independence -0.45§ -0.41§
Activities of daily living -0.49§
Working capacity -0.56ƒ
Social relationships -0.42§ -0.47ƒ
Personal relationships -0.54ƒ -0.56§
Social support -0.40§ -0.42§
Sexual activity 0.45§
Environment -0.41§ -0.54ƒ -0.72§
Physical safety and security -0.48§
Home environment -0.44§ -0.52§
Financial resources -0.48ƒ -0.56§
Participating in and possibilities for recreaction/leisure -0.43§ -0.50ƒ -0.52§
Physical environmentz -0.46§ -0.54ƒ -0.45§ -0.74**
Data presented are correlation coefficients. Bold text represents domains with facets listed underneath; nonsignificant facets
have not been included in the table. #: I: BBS physical sensations; II: BBS Affective/evaluative; III: BBS Low energy; IV: BBS
Hyperventilation/speechless; Total: total BBS score; }: Thinking, learning, memory, and concentration; z: pollution/noise/
traffic/climate. Higher scores on QOL facets and domains indicate better QOL. Exceptions are the facets ’pain and
discomfort9 and ’negative feelings9. §: pv0.05; ƒ: pv0.01; **: pv0.001.
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Subjective dyspnoea, especially the effective/evalua-
tive and low energy scales, appeared to be correlated
with many domains and various aspects of QOL.
However, subjective dyspnoea was not related to the
pulmonary function parameters which are measures of
lung capacity and thus, indirectly, objective dyspnoea
measures. Patients9 perception of dyspnoea is not
associated with objective breathlessness measures. The
regression analysis showed that the male IPF patients
and patients with a low score on effective/emotional
breathlessness indicated a better overall QOL.
The major QOL problems of the IPF patients
appeared to be fatigue, mobility, activities of daily
living, and working capacity. As mentioned above,
none of these QOL aspects was significantly related to
the lung function parameters. Although abnormal
physical exhaustion and fatigue are often regarded as
a natural consequence of pulmonary diseases, in
line with the present observations, Gugger [21]
assumed that, apart from factors specifically related
to pulmonary diseases, psychosocial factors are mainly
responsible for the impaired physical fitness and
fatigue. Therefore, it was recommended that a careful
evaluation of psychological aspects be included in the
diagnostic evaluation of patients suffering from a
certain pulmonary disorder [21]. Moreover, the assess-
ment, support, and reinforcement of a patient9s
psychosocial assets and ability to cope with chronic
respiratory difficulty can help enhance the QOL, and
decrease feelings of fear for the manifestations and/or
treatments of disease [22 – 24].
The patients9 perception regarding the severity of
their illness was not related to objective measures of
severity and illness duration. This indicates that the
patients9 own opinions about the severity of their
disease is not in accordance with objective data. This is
in alignment with the fact that patients frequently
report subjective improvement despite no objective
improvement [1, 2, 5, 6]. Possible explanations are that:
1) patients suppress information concerning the serious-
ness of their disease; 2) patients have psychologically
adapted to their situation; and/or: 3) patients feel
that their situation is better than indicated by their
physicians. Which of these reasons play a key role,
needs to be explored.
Perceiving IPF as a severe disease is related to
impaired physical health, as well as reduced feelings of
independence from others. More specifically, disease
severity is associated with more pain, more fatigue, an
impaired working capacity and more dependency on
medication. Thus, the perceived seriousness of IPF has
a negative influence on patients9 QOL. Surprisingly,
perceiving IPF as a severe illness was related to more
sexual activity. Presumably, patients want to enjoy life
as much as possible and, therefore, take advantage of
their sexual activity, in one of its many forms, as long
as possible. Studies among populations of rheumatoid
arthritis, psoriasis, and sarcoidosis patients [25, 26]
revealed no sexual difficulties.
Remarkably, the perceived seriousness of IPF, as
well as fatigue scores, were not related to depressed
mood. In a study among sarcoidosis patients, a
relationship was found between fatigue and depression
scores [13]. The authors realize that the sample size was
rather small. Therefore, these results should be inter-
preted with care. A larger study is needed in order to
replicate the results from the present study. However,
considering the high correlation between the BDI and
the WHOQOL-100 facet "negative feelings", using a
separate measure for assessing depressive mood seems
to be redundant. Further studies exploring this issue
are required.
In the present study, 23.5% of the patients who fully
completed the BDI had a score indicative of significant
depressive symptoms. Using the CDI score, which
excludes physical symptoms of depression, comparable
results emerged. In another study, IPF patients who
participated in focus groups spontaneously mentioned
feelings of depression [7]. It emerges that more
attention should be paid to the negative feelings of
IPF patients. The fact that general fatigue (measured
with the WHOQOL), a symptom of clinical depression,
was unrelated to the BDI/CDI scores implies that
although IPF patients are bothered by negative
feelings, they are in general, not clinically depressed.
The relationship between the CDI and the breath-
lessness scale "low energy" (physical fatigue) might
indicate that dyspnoea causes fatigue. Previously, it
appeared, that in a group of sarcoidosis patients [13],
the presence of symptoms played a major role
regarding those feelings. Moreover, sarcoidosis patients
with complaints demonstrated higher BDI scores
compared to patients without complaints [27].
Most of the aspects of impaired QOL in IPF are
not measured by disease-specific health status (or
nowadays also called health-related QOL) lung
questionnaires such as the St. George9s Respiratory
Questionnaire (SGRQ). QOL has a much wider scope
than the physical, emotional, and social domains
usually studied in health status measures. Health
status measures assess fewer aspects and, therefore,
provide less specific information concerning patients9
problems. Moreover, aspects such as fatigue are not
usually assessed in health status measures. Further-
more, QOL instruments measure a person9s own
evaluation of their functioning, whereas health status
measures assess patients9 physical, emotional and social
functioning [7, 28]. The reliability and validity of the
WHOQOL-100 are high [14]. Within a group of
sarcoidosis patients the WHOQOL-100 distinguishes
well between patients with and without complaints
[13, 15]. Previously, it was established that the
WHOQOL-100 was preferable to the SGRQ in IPF
[7]. Reasons were, for instance, that focus group
participants made substantial negative remarks about
the SGRQ, the scales of this questionnaire were not
mentioned as important aspects of life and the SGRQ
only measures three aspects (symptoms, activity, and
impact). This provides very limited information with
regard to problems that patients may experience [7]. In
line with this, results from the present study indicate
that the WHOQOL-100 appeared to be useful in IPF.
In contrast, Chang et al. [29] studied a group of
interstitial lung disease patients (33 IPF, 10 sarcoidosis,
seven miscellaneous) and concluded that the Short
Form 36 Item Questionnaire (SF-36) and SGRQ are
good tools for measuring health-related QOL or health
status. The discrepancy between their findings and
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other previous findings [7] might be caused by the fact
that focus groups were used in other studies, in which
IPF patients themselves could comment on the
measures and did not rely solely on psychometrics.
The SF-36 might be a good measure for assessing
health status in IPF. The choice between a health status
measure and a QOL measure should be based on the
aim of a study [28]. If the interest is only in functioning,
then the SF-36 might be suitable [29, 30]. However, if
the interest is in the opinion of the patients, then the
WHOQOL-100 is a suitable measure. Before using the
SF-36, the usefulness and acceptability of the instru-
ment should be studied from the patients9 view
point with, for example, focus groups or individual
interviews.
Although the severity, disablement and shortened
life expectancy of IPF might be comparable with
another serious illness such as cancer, less attention has
been paid to these issues and until now hardly any
rehabilitation programmes have been prepared for
patients suffering from IPF. This study intended to
focus on the aspects of QOL impairment of IPF
patients. Rehabilitation programmes should be deve-
loped to improve the knowledge of patients and their
families about the severity of the disease and to
improve adaptive coping with the disease. In a study
among chronic leukaemia patients, coping reflected the
different strategies adopted to manage patients9 capa-
city for getting through difficult times. The adaptive
strategy action included acquiring as much information
as possible about their disease [31].
In conclusion, the quality of life of idiopathic
pulmonary fibrosis patients was mainly impaired in
the areas "physical health" and "level of independence".
Perceived seriousness of idiopathic pulmonary fibrosis
was related to the same quality of life domains. The
World Health Organization Quality of Life assessment
instrument-100 facet "negative feelings" appeared to
be useful to assess depressive mood. Fatigue was
unrelated to the depressive mood. Furthermore,
although quality of life aspects were related to lung
function impairment, it only concerned nonimpaired
aspects. Subjective breathlessness was associated with
depressive mood and quality of life. Finally, sex and the
effective/emotional breathlessness scale were the only
predictors of overall quality of life. Therefore, it is
reasonable to assume that the assessment, support and
reinforcement of a patient9s psychosocial assets and
ability to cope with idiopathic pulmonary fibrosis can
help enhance the quality of life. Moreover, these
aspects should be a primary consideration in the
development of rehabilitation programmes for patients
suffering from idiopathic pulmonary fibrosis as well as
pathophysiological aspects of this severe pulmonary
disorder.
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